GlaxoSmithKline Q3 Results - Q3 Top Pharma Company Earnings Reports

View GlaxoSmithKline's Q3 Earnings Report

FiercePharma says: Emerging markets are paying off for GlaxoSmithKline, but it's pandemic flu that's really accelerating sales. Third-quarter profits jumped by 30 percent to £1.34 billion ($2.18 billion), partly on currency effects, while sales grew 15 percent to £6.76 billion ($11.05 billion). Read more...


  • Return to sales growth with Q3 turnover +3% CER; +15% sterling
  • Continued improvement expected in Q4
  • Portfolio diversification and investment in key areas drives return to sales growth: Emerging Markets (+25%); Japan (+19%) and Consumer Healthcare (+8%)
  • Further growth expected in Q4 2009 including significant sales of influenza products
  • US sales -12% primarily due to continued adverse impact of generic competition

Check out GSK's current estimates from CNN Money

GSK's Website:

GlaxoSmithKline Q3 Results - Q3 Top Pharma Company Earnings Reports

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.